Artificial Intelligence in Indonesian Healthcare

By Sumona Bose

February 14, 2024

AI’s Rising Influence in Global Healthcare

Artificial intelligence (AI) is making waves in the healthcare industry worldwide. OpenAI’s ChatGPT, an AI language model, astounded the medical community by acing the United States Medical Licensing Exam without specialised training. Google’s Med-PaLM 2 mirrored this success, demonstrating AI’s potential to absorb and apply vast medical knowledge. AI’s  power also extends to research, with McMaster University and MIT using it to discover new antibacterial molecules, marking a significant step in the fight against antimicrobial resistance. The East Asian and Pacific region has also seen greater increase in AI employability in healthcare market.

Asia Pacific Healthcare AI Market Growth Outlook 2021-2027
Figure 1: Asia Pacific’s AI Market Report.

AI and Healthcare in Indonesia: Opportunities and Challenges

Indonesia, with its low physician-to-population ratio, stands to benefit immensely from AI’s potential. AI-powered chatbots, integrated with data from various sources, could enhance healthcare accessibility across the archipelago. The integration of AI with digital health platforms like Halodoc could potentially improve the quality of healthcare services in Indonesia. However, the journey towards AI integration is not without challenges. Bias in AI models, primarily trained on medical literature from high-income countries, is a significant concern. Indonesia must consider this bias when integrating AI with existing digital healthcare services. The use of local data, such as from Halodoc, is crucial for effective AI deployment in Indonesian healthcare.

Addressing Privacy Concerns and the Need for Regulation

Data acquisition for AI model training also raises serious privacy concerns. Despite the enactment of the Personal Data Protection Law in 2022, public unease over sensitive data leaks remains high in Indonesia. The country can learn from South Korea’s model of a centralised, secure, and ethical data-sharing system to build its national AI-based healthcare data ecosystem. The future of AI-enhanced healthcare necessitates a reimagining of healthcare education. Future professionals must be prepared to synergise with AI, requiring the development of AI-focused modules in medical and health curricula. By promoting stringent regulations, prioritising data privacy, and reimagining healthcare education, Indonesia can pave the way for a future where AI and human expertise harmoniously work together.

In conclusion, the integration of AI in healthcare presents a promising future for Indonesia. With careful consideration of potential challenges and the implementation of robust regulations, the country can leverage AI’s potential to improve healthcare accessibility and quality across the archipelago.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.